[3]
Sabbah, D.A.; Hajjo, R.; Sweidan, K. Review on Epidermal Growth Factor Receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr. Top. Med. Chem., 2020, 20(10), 815-834.
[4]
Zhong, H.; Bowen, J.P. Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways. Curr. Top. Med. Chem., 2011, 11, 1571-1590.
[5]
Uko, N.E.; Güner, O.F.; Matesic, D.F.; Bowen, J.P. Akt Pathway Inhibhitors. Curr. Top. Med. Chem., 2020, 20(10), 835-846.
[6]
Sabbah, D.A.; Brattain, M.G.; Zhong, H. Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go? Curr. Med. Chem., 2011, 18(36), 5528-5544.
[7]
Sabbah, D.A.; Hu, J.; Zhong, H.A. Advances in the development of class I phosphoinositide 3-kinase (PI3K) inhibitors. Curr. Top. Med. Chem., 2016, 16(13), 1413-1426.
[8]
Liang, J.J.; Wang, J.Y.; Zhang, T.J.; An, G.S.; Ni, J.H. Li., S.Y.; Jia, H.T. MiR-509-3-5p-NONHSAT112228.2 axis regulates p21 and suppresses proliferation and migration of lung cancer cells. Curr. Top. Med. Chem., 2020, 20(10), 847-854.
[9]
Bartzatt, R. Prostate cancer: Biology, incidence, detection methods, treatment methods, and vaccines. Curr. Top. Med. Chem., 2020, 20(10), 855-882.
[10]
Slater, O.; Miller, B. and; Kontoyianni, M. Decoding protein-protein Interactions: An overview. Curr. Top. Med. Chem., 2020, 20(10), 883-900.
[11]
Proctor, N.K.; Ertan-Bolelli, T.; Bolelli, K.; Taylor, E.W.; Chiu, N.H.L.; Bowen, J.P. Towards a better understanding of computational models for predicting DNA methylation effects at the molecular level. Curr. Top. Med. Chem., 2020, 20(10), 901-909.
[12]
Lapinska, K.; Faria, G.; Mcgonagle, S.; Macumber, K.M.; Heerboth, S.; Sarkar, S. Cancer progenitor cells: The result of an epigenetic event? Anticancer Res., 2018, 38, 1-6.